HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NovaLash Adds Peptide-Based Eyelash "Fortifier" To Its Line Of Extensions

This article was originally published in The Rose Sheet

Executive Summary

NovaLash is adding peptide-enriched Lash+Doctor -- formulated to "strengthen" and "visibly lengthen" eyelashes, according to the company -- to its offering of products designed to create the illusion of fuller lashes

You may also be interested in...



Allergan Creating Awareness For Game-Changing Latisse Eyelash Growth Drug

Allergan is preparing a multi-pronged marketing campaign to make lash-light consumers aware of its recently approved Latisse drug; it remains to be seen how availability of a prescription product with clinically demonstrated effectiveness will impact sales of cosmetic eyelash enhancers

Unilever’s Dove Recommits To ‘Real Women’ Against Rising AI Threat

Unilever PLC’s Dove and Baby Dove brands continue tackling prominent social causes with a vow to be responsible about representing women realistically in advertising in the age of AI and a renewed commitment to closing the Black maternal care gap.

L’Oreal Joins J&J And Major Retailers Defending Benzene Class Actions In Federal Courts

Benzoyl peroxide-based acne drug products and their alleged proclivity to become contaminated with carcinogenic benzene are at the center of putative class actions filing against L’Oreal in federal courts around the US.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016250

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel